Early Human Development, 15 (1987) 373—374
Elsevier Scientific Publishers Ireland Ltd.

Subject index

γ-glutamyltransferase, liver disease, phenobarbitone treatment, parenteral nutrition, 213
age correction, premature, first-year development, 257
antenatal dexamethasone, neutrophil adherence, 265
antenatal diagnosis, congenital chylothorax, resuscitation, pleuro-amniotic shunting, 365
auditory evoked responses, hyperbilirubinaemia, sensorineural deafness, 269

banked mature human milk, very low birth weight, proportional growth, 279
blood polyamines, spermidine, spermine, diet, 323
breast milk, latex nipple shield, suckled milk samples, fat intake, 295

collagen, fetal growth retardation, human lung, pulmonary development, hyaline membrane disease, surfactant, 203
congenital chylothorax, resuscitation, pleuro-amniotic shunting, antenatal diagnosis, 365
continuous subcutaneous insulin infusion, type-1-diabete mellitus, fetal behavioural states, fetal movements, real-time ultrasound, 231

diet, spermidine, spermine, blood polyamines, 323
diurnal variation, fetal movements, fetal heart rate, second trimester of pregnancy, normal pregnancy, 333
Doppler flow velocity waveform, peripheral vascular resistance, placental embolization, 119

erythrocyte, fatty acid, phospholipid, neonate, 85

fatty acid, erythrocyte, phospholipid, neonate, 85
fat intake, latex nipple shield, breast milk, suckled milk samples, 295
fetal behavioural states, type-1-diabetes mellitus, continuous subcutaneous insulin infusion, fetal movements, real-time ultrasound, 231
fetal growth retardation, collagen, human lung, pulmonary development, hyaline membrane disease, surfactant, 203
fetal heart rate, diurnal variation, fetal movements, second trimester of pregnancy, normal pregnancy, 333
fetal movements, diurnal variation, fetal heart rate, second trimester of pregnancy, normal pregnancy, 333
fetal movements, type-1-diabetes mellitus, continuous subcutaneous insulin infusion, fetal behavioural states, real-time ultrasound, 231
first-year development, age correction, premature, 257

G6PD deficiency, jaundice, hyperbilirubinaemia, 317
growth retardation, intra-uterine growth, nutrition, 329

health newborn, heart rate, spectral analysis, newborn-at-risk, Respiratory Sinus Arrhythmia, 349
heart rate, spectral analysis, healthy newborn, newborn-at-risk, Respiratory Sinus Arrhythmia, 349
human lung, collagen, fetal growth retardation, pulmonary development, hyaline membrane disease, surfactant, 203
hyaline membrane disease, collagen, fetal growth retardation, human lung, pulmonary development, surfactant, 203
hyperbilirubinaemia, jaundice, G6PD deficiency, 317
hyperbilirubinaemia, sensorineural deafness, auditory evoked responses, 269

intra-uterine growth, growth retardation, nutrition, 329

jaundice, hyperbilirubinaemia, G6PD deficiency, 317

latex nipple shield, breast milk, suckled milk samples, fat intake, 295
liver disease, γ-glutamyltransferase, phenobarbitone treatment, parenteral nutrition, 213

neonate, fatty acid, erythrocyte, phospholipid, 85
neutrophil adherence, antenatal dexamethasone, 265
newborn-at-risk, heart rate, spectral analysis, healthy newborn, Respiratory Sinus Arrhythmia, 349
normal pregnancy, diurnal variation, fetal movements, fetal heart rate, second trimester of pregnancy, 333
nutrition, intra-uterine growth, growth retardation, 329

parenteral nutrition, γ-glutamyltransferase, liver disease, phenobarbitone treatment, 213
peripheral vascular resistance, Doppler flow velocity waveform, placental embolization, 119
phenobarbitone treatment, γ-glutamyltransferase, liver disease, parenteral nutrition, 213
phospholipid, fatty acid, erythrocyte, neonate, 85
placental embolization, Doppler flow velocity waveform, peripheral vascular resistance, 119
pleuro-amniotic shunting, congenital chylothorax, resuscitation, antenatal diagnosis, 365
pregnancy, sirenomelia, 217
premature, age correction, first-year development, 257
proportional growth, very low birth weight, banked mature human milk, 279
pulmonary development, collagen, fetal growth retardation, human lung, hyaline membrane disease, surfactant, 203

randomized trial, respiratory distress syndrome, very early nasopharyngeal distending pressure, 21
real-time ultrasound, type-1-diabetes mellitus, continuous subcutaneous insulin infusion, fetal behavioural states, fetal movements, 231
respiratory distress syndrome, randomized trial, very early nasopharyngeal distending pressure, 21
Respiratory Sinus Arrhythmia, heart rate, spectral analysis, healthy newborn, newborn-at-risk, 349
resuscitation, congenital chylothorax, pleuro-amniotic shunting, antenatal diagnosis, 365

second trimester of pregnancy, diurnal variation, fetal movements, fetal heart rate, normal pregnancy, 333
sensorineural deafness, hyperbilirubinaemia, auditory evoked responses, 269
sirenomelia, pregnancy, 217
spectral analysis, heart rate, healthy newborn, newborn-at-risk, Respiratory Sinus Arrhythmia, 349
spermidine, spermine, blood polyamines, diet, 323
spermine, spermidine, blood polyamines, diet, 323
suckled milk samples, latex nipple shield, breast milk, fat intake, 295
surfactant, collagen, fetal growth retardation, human lung, pulmonary development, hyaline membrane disease, 203

type-1-diabetes mellitus, coninuous subcutaneous insulin infusion, fetal behavioural states, fetal movements, real-time ultrasound, 231

very early nasopharyngeal distending pressure, respiratory distress syndrome, randomized trial, 21
very low birth weight, banked mature human milk, proportional growth, 279

Early Human Development, 15 (1987) 375
Elsevier Scientific Publishers Ireland Ltd.

Author index

Aber, V., 147, 203
Aboualfa, M., 45
Amatayakul, K., 295
Anlar, Y., 265
Anlar, B., 265
Axelsson, O., 95

Bacciottini, F., 323
Baum, J.D., 295
Bekedam, D.J., 231
Benhaiem-Sigaux, N., 33
Bernasconi, S., 323
Berseus, O., 1,11
Beverley, D.W., 21
Bloch, G., 33
Boardman, K.M., 103
Booth, P., 365
Brabyn, D.G., 21

Cartlidge, P.T.H., 213
Casasoprana, A., 33
Casti, A., 323
Chance, G.W., 21
Cinkotai, K.I., 103
Clarson, C., 21
Cnattingius, S., 95
Cooke, R.W.I., 197
Cutillo, S., 317

Davies, D.P., 329
De Lucchi, C., 85
De Vries, L.S., 269
De Vries, J.I.P., 333
Desai, R., 147, 203
Dubowitz, L.M.S., 269
D'Souza, S.W., 103

Eiselt, M., 349
Excler, J.-L., 279
Eyre, J.A., 45

Faus, M.J., 85
Filbey, D., 1, 11
Frenzel, J., 349
Frezza, E., 323

Gamsu, H.R., 365
Gau, G.S., 221
Gil, A., 85
Gonzales, M., 33
Greenough, A., 365
Gremo, F., 165

Hammarlund, K., 95
Han, V.K.M., 21
Hislop, A.A., 147
Holdiness, M.R., 61

Imong, S.M., 295

Jackson, D.A., 295
Jakobovits, A., 131
Jakobovits, A.A., 131

Koivu, M., 75

Lakhani, P., 103
Lary, S., 269
Lasne, Y., 279
Laywood, E., 137
Lee, N., 329
Leung, S., 329
Levene, M., 137
Lindeberg, S., 11
Lo, L., 329
Lotgering, F.K., 119
Lui, S., 329
Luzatto, L., 317

Malinger, G., 217
Marcello, C., 165
Marchisio, A.M., 165
Matilainen, R., 257
McLeod, C.N., 295
Meloni, T., 317
Mobberley, M.A., 221
Morley, C.J., 197
Mulas, M.L., 165
Mulder, E.J.H., 231, 333
Mulliez, N., 33

Nicolaides, K.H., 365
Noordam, M.J., 119

Orlandini, G., 323

Palomba, M., 165
Periago, J.L., 85
Picard, J., 279
Pitta, M.L., 85
Prechtl, H.F.R., 231, 333

Rantakallio, P., 75
Razavi-Encha, F., 33
Reali, N., 323
Redman, C.W.G., 45
Rennie, J.M., 197
Rip, M.R., 113
Rosen, N., 217
Rosenthal, M., 137
Rother, M., 349
Roux, C., 33
Rutter, N., 213
Ryder, T.A., 221

Sandstrom, B., 1
Sann, L., 279
Shaheed, W.A., 21
Sinha, S., 137
Struijk, P.C., 119
Sumabat, W.O., 21

Testa, U., 317
Tonge, H.M., 119
Torelli, S., 165
Treschan, O., 217

Viski, A., 131
Visser, G.H.A., 231, 333
von Wendt, L., 75

Waters, H.M., 103
Wesström, G., 1, 11
Whitelaw, A.G., 269
Wigglesworth, J.S., 147, 203
Wilkinson, A.R., 45
Witte, H., 349
Wladimiroff, J.W., 119
Wongsawat, L., 295
Woods, D.L., 113
Woolridge, M.W., 295

Yudkin, P.L., 45
Yutabootr, Y., 295

Zakut, H., 217
Zannino, L., 323
Zwacka, G., 349
Zwiener, U., 349